ClinicalTrials.gg
RecruitingNCT06073106OPTIMA-CUpdated Oct 2, 2026

Targeting Osteosarcopaenia and Multimorbidity for Frailty Prevention

An observational study in Stroke, Traumatic Brain Injury and Knee Osteoarthritis, sponsored by Tan Tock Seng Hospital. Recruiting at 1 site in Singapore. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Tan Tock Seng Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Oct 2, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Stroke by Tan Tock Seng Hospital — 3 open to participants now, 6 under way, none of them phase 3. Stroke · Tan Tock Seng Hospital.

Started
2025
with 2 others
Observational
9 of 29
1 open now
Registered
19th of 29
by date

Among the 29 studies in Stroke by Tan Tock Seng Hospital, this one is one of 3 that started in 2025, is one of 9 observational ones, and was the 19th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

3 of the 29 studies in Stroke by Tan Tock Seng Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Stroke by Tan Tock Seng Hospital, or all of them as a file.
02

Study summary

The aging population and its accompanying burden from non-communicable chronic diseases predicts an increasing impact imposed by frailty on healthcare systems. This is due to a lack of normative data for older adults and reliable risk stratification methods to develop effective approaches to the prevention of frailty.

In this study, the investigators plan to form a common dataset for phenotype identification, risk stratification of frailty and its targeted treatment plans in the at-risk and mildly frail population.

Read the detailed description

Osteosarcopaenia and multimorbidity have emerged as two key antecedent factors driving the cycle of frailty, leading to adverse outcomes. However, it remains unclear how multimorbidity and/or osteosarcopaenia act singly or in concert to influence the expression and trajectory of the frailty continuum.

OPTIMA-C will develop unifying administrative and data platforms, exploring the feasibility of inclusive screening for sarcopaenia early during rehabilitation hospital stay. Early muscle ultrasound will also be utilised to determine key muscles possibly predictive of rehabilitation functional or global outcomes in the studied populations and their correlation with acute disease outcomes. Digital markers are quantified and correlations are investigated with physical, muscle and bone imaging findings.

03

Conditions studied

  • Stroke
  • Traumatic Brain Injury
  • Knee Osteoarthritis
  • Breast Cancer

Keywords

  • Frailty
  • Multimorbidity
  • Osteosarcopaenia
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients in both outpatient and inpatient clinics

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 50y
  2. Asian ethnicity
  3. First diagnosis (stroke, Traumatic Brain Injury (TBI), knee osteoarthritis, breast cancer)
  4. Living in community
  5. Able to understand 1 step simple commands
  6. For inpatients: (i) within 12 weeks of disease (stroke/TBI) onset, and (ii) within 2 weeks of rehabilitation ward admission
  7. For outpatients: (i) >6 months from initial diagnosis of first stroke, TBI, knee osteoarthritis or breast cancer, and (ii) at least standby assistance, modified independent or independent in ambulation with /without walking.

Exclusion criteria

Exclusion Criteria:

  1. Nursing home or dormitory resident
  2. Non-resident status in Singapore (e.g. foreign worker, tourist, temporary visit pass)
  3. Impairments affecting understanding of questionnaires and tasks: e.g. severe deafness, severe visual impairment and severe /global aphasia,
  4. Presence of active fractures, dislocations, non-weight bearing status, burns, unhealed wounds, active skin infections/eczema and agitated behaviour or delirium
  5. Anticipated \< 1 year
  6. Presence of tracheostomy, ventilator, renal dialysis, end-organ failure
  7. Patients with disorders of consciousness.
  8. Pregnant or lactating participants

    For Knee Osteoarthritis patients only:

  9. Alternative diagnosis to knee OA e.g. Referred pain from hip or spine.
  10. Other forms of knee arthritis eg. Inflammatory, post traumatic
  11. Previous knee arthroplasty
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Stroke

    Both acutely admitted stroke patients undergoing rehabilitation and chronic recovered stroke outpatients will be recruited.

  • Traumatic Brain Injury

    Both acutely admitted TBI patients undergoing rehabilitation and chronic recovered TBI outpatients will be recruited.

  • Breast Cancer

    Only recovered breast cancer patients.

  • Knee Osteoarthritis

    For patients with chronic knee osteoarthritis.

06

What researchers measure

Primary outcomes

  1. Incidence (rates) of Frailty

    Based off different outcomes determined in the study

    Time frame: Through study's data collection period, up to 4 years

  2. Severity of Frailty

    Based on CFS - 9-point clinical assessment tool evaluating an individual's frailty status; maximum score: 9; higher score indicates increased frailty.

    Time frame: For inpatient: Visit 1 (within 2 weeks of admission) to Visit 6 (end of 3rd year); For outpatient: Visit 1 (baseline) to Visit 4 (end of 3rd year)

Secondary outcomes

  1. Body Composition Analysis (BCA)

    Measured using weak electrical current passed from feet to estimate proportion of muscle, fat and water mass.

    Time frame: For inpatient: Visit 3 (6 months post-event) to Visit 6 (end of 3rd year); For outpatient: Visit 1 (baseline) to Visit 4 (end of 3rd year)

  2. Short Physical Performance Battery (SPPB)

    Measures 3 components: (1) 5 times chair stand test; (2) Balance test; (3) Gait speed (4m walk test). Score from 0-12 with higher score indicating greater functional capacity.

    Time frame: For inpatient: Visit 1 (within 2 weeks of admission) to Visit 6 (end of 3rd year); For outpatient: Visit 1 (baseline) to Visit 4 (end of 3rd year)

  3. Hand Grip Strength (kg)

    Measured seated with arms on a table bent to 90° using a dynamometer (mean of 3 readings will be recorded)

    Time frame: For inpatient: Visit 1 (within 2 weeks of admission) to Visit 6 (end of 3rd year); For outpatient: Visit 1 (baseline) to Visit 4 (end of 3rd year)

  4. Muscle Ultrasound imaging

    Determines state of muscle health of arm, thigh and jaw muscles through size, area and structural properties.

    Time frame: For Inpatient: Visit 1 (within 2 weeks of admission), Visit 2 (1 week pre-discharge)

  5. FRAIL Questionnaire

    5-point questionnaire; (1-2 point) indicates pre-frail, (3-5 points) indicates frail

    Time frame: For inpatient: Visit 1 (within 2 weeks of admission) to Visit 6 (end of 3rd year); For outpatient: Visit 1 (baseline) to Visit 4 (end of 3rd year)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Tay MRJ, Kim JM, Ong PL, Khin LW, Wong CJ, Kong KH, Tan BY, Lee ES, Sim SZ, Lim WS, Yam MGJ, Chew JL, Tan AWK, Sidarta A, Yee E, Chua KSG. Targeting osteosarcopenia and multimorbidity for frailty prevention through identification and deep phenotyping methods in healthy ageing and high-burden disease cohorts (OPTIMA-C): a longitudinal observational cohort study protocol for neuromusculoskeletal muscle health. BMJ Open. 2025 May 23;15(5):e094279. doi: 10.1136/bmjopen-2024-094279. PubMed 40409965 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.

Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 24 months is below that.

Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2023
First posted
Oct 10, 2023
StartActual
Jan 1, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Tan Tock Seng Hospital · Singapore, Singapore
Show 1 removed
  • Tan Tock Seng Hospital · Singapore, Singapore
Oct 2, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40409965 ↗
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40409965 ↗
    1 site added, 1 site removed
    Show site
    • Tan Tock Seng Hospital · Singapore, Singapore
    Show 1 removed
    • Tan Tock Seng Hospital · Singapore, Singapore
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06073106
Collaborators
Rehabilitation Research Institute of Singapore (RRIS), Woodlands Health (WH)
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Jan 1, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Low Ai Mei Jaclyn
Contact
Jaclyn_AM_LOW@ttsh.com.sg
68894580
Karen Chua
principal investigator · Tan Tock Seng Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion